The city of Beijing is full of vitality and brilliance. From November 22 to November 24, 2024, the 17th Health Service Industry Conference and the 15th National Congress on Health Management Chinese Medical Association were grandly held at the Beijing National Convention Center. Renowned experts and scholars from China's health management industry gathered together to exchange and showcase the latest theoretical and practical innovations in health management, discuss the latest developments in health management research, and bring about a wonderful annual event.

At the 5G+Three Early Health Management Forum held on the afternoon of November 23, Professor Liu Zhong, Director of the Health Management Center of the First Affiliated Hospital of Zhejiang University School of Medicine, delivered a keynote speech titled "Empowering Comprehensive Liver Cancer Early Screening, Diagnosis, and Health Management System from Grassroots to Top Level". Director Liu gave a detailed and exciting presentation on the exploration of health management models for early screening and diagnosis of liver cancer, as well as the use of miRNA7 as an innovative technology to empower early diagnosis and treatment of liver cancer, which received widespread praise from attending experts.

Director Liu first introduced that in recent years, the incidence rate of liver cancer in China has increased year by year, and the prevention and treatment of liver cancer needs urgent attention. According to the outline of the "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)", it is necessary to further promote early cancer screening and early diagnosis and treatment, establish a hierarchical liver cancer screening system, and strengthen the promotion of cancer prevention and treatment research achievements, so as to achieve the goal of an overall 5-year cancer survival rate of 46.6% by 2030. Exploring new technologies and indicators, such as miRNA and other new liver cancer markers or marker combinations, and exploring risk prediction models suitable for Chinese people are effective measures to achieve the goal of cancer prevention and control and build a healthy China. Through the integrated "pyramid" liver cancer screening management model that progresses layer by layer and gradually condenses, exploring the initial screening, fine screening, and early diagnosis route for chronic liver disease populations can help achieve early screening, diagnosis, and treatment of high-risk liver cancer populations, ultimately improving the 5-year survival rate of liver cancer populations.

She pointed out that the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)" explicitly use miRNA7 as an early diagnostic biomarker for liver cancer, and the significance of early detection, diagnosis, and monitoring of primary liver cancer based on 7 miRNA combinations is mentioned in 12 places throughout the text. The detection rate of extremely early liver cancer using a liver cancer diagnostic model based on seven plasma miRNAs is as high as 86.1%, which is 30% higher than the traditional biomarker AFP; The sensitivity and specificity for AFP negative liver cancer were 77.7% and 84.5%, respectively, which were significantly better than traditional biomarker detection (Evidence Level 1, Recommendation A). According to the diagnostic roadmap for liver cancer, for high-risk individuals, nodules with a diameter of ≤ 1cm in the liver are found. If a definitive diagnosis cannot be made, imaging examinations can be conducted every 2-3 months for follow-up, combined with serum AFP, 7 microRNA combinations, etc., to confirm the diagnosis. In summary, miRNA7 can significantly improve the detection rate of very early liver cancer and is also significantly superior to other traditional liver cancer markers in terms of recurrence monitoring, especially for AFP negative populations.

She further introduced that miRNA7 can be used for the full process management of liver cancer: for the physical examination department, miRNA7 can be used for early screening and detection to indicate the possible risk of liver cancer occurrence in advance; For departments related to the liver, it can play an auxiliary diagnostic role for high-risk populations, significantly reducing the missed/incorrect diagnosis rate caused by traditional biomarker testing; In departments related to liver surgery, in addition to assisting in diagnosis, miRNA7 can also play a role in dynamic monitoring, helping to indicate the recurrence risk of liver cancer patients after surgery and buying more valuable time for patients to receive treatment again. Therefore, miRNA7 has a wide range of clinical applications, involving high-risk and diagnosed liver cancer populations, with enormous market potential.

This forum unites and consolidates colleagues in the academic community of health management, comprehensively exchanges and discusses the latest practices and development achievements of the health service industry and health management discipline, explores innovative health management service models, and provides technological empowerment for the development of the health service industry.

I hope that in the future, through the wider development and use of miRNA7 in clinical practice, it can improve the treatment effectiveness and quality of life of more liver cancer patients, actively promote the implementation of the tumor full cycle management system, and help China's liver cancer diagnosis and treatment level reach a new height.